387 related articles for article (PubMed ID: 31593317)
1. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer.
Fan D; Ma J; Bell AC; Groen AH; Olsen KS; Lok BH; Leeman JE; Anderson E; Riaz N; McBride S; Ganly I; Shaha AR; Sherman EJ; Tsai CJ; Kang JJ; Lee NY
Cancer; 2020 Jan; 126(2):444-452. PubMed ID: 31593317
[TBL] [Abstract][Full Text] [Related]
2. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base.
Pezzi TA; Mohamed ASR; Sheu T; Blanchard P; Sandulache VC; Lai SY; Cabanillas ME; Williams MD; Pezzi CM; Lu C; Garden AS; Morrison WH; Rosenthal DI; Fuller CD; Gunn GB
Cancer; 2017 May; 123(9):1653-1661. PubMed ID: 28026871
[TBL] [Abstract][Full Text] [Related]
3. Association of Treatment Strategies and Tumor Characteristics With Overall Survival Among Patients With Anaplastic Thyroid Cancer: A Single-Institution 21-Year Experience.
Wu SS; Lamarre ED; Yalamanchali A; Brauer PR; Hong H; Reddy CA; Yilmaz E; Woody N; Ku JA; Prendes B; Burkey B; Nasr C; Skugor M; Heiden K; Chute DJ; Knauf JA; Campbell SR; Koyfman SA; Geiger JL; Scharpf J
JAMA Otolaryngol Head Neck Surg; 2023 Apr; 149(4):300-309. PubMed ID: 36757708
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.
Rao SN; Zafereo M; Dadu R; Busaidy NL; Hess K; Cote GJ; Williams MD; William WN; Sandulache V; Gross N; Gunn GB; Lu C; Ferrarotto R; Lai SY; Cabanillas ME
Thyroid; 2017 May; 27(5):672-681. PubMed ID: 28068873
[TBL] [Abstract][Full Text] [Related]
5. Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease.
Beckham TH; Romesser PB; Groen AH; Sabol C; Shaha AR; Sabra M; Brinkman T; Spielsinger D; McBride S; Tsai CJ; Riaz N; Tuttle RM; Fagin JA; Sherman EJ; Wong RJ; Lee NY
Thyroid; 2018 Sep; 28(9):1180-1189. PubMed ID: 30105947
[TBL] [Abstract][Full Text] [Related]
6. Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma.
Nachalon Y; Stern-Shavit S; Bachar G; Shvero J; Limon D; Popovtzer A
JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1128-32. PubMed ID: 26512447
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy Plus Chemotherapy Leads to Prolonged Survival in Patients With Anaplastic Thyroid Cancer Compared With Radiotherapy Alone Regardless of Surgical Resection and Distant Metastasis: A Retrospective Population Study.
Zhou W; Yue Y; Zhang X
Front Endocrinol (Lausanne); 2021; 12():748023. PubMed ID: 34790169
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic thyroid carcinoma: a 25-year single-institution experience.
Mohebati A; Dilorenzo M; Palmer F; Patel SG; Pfister D; Lee N; Tuttle RM; Shaha AR; Shah JP; Ganly I
Ann Surg Oncol; 2014 May; 21(5):1665-70. PubMed ID: 24554064
[TBL] [Abstract][Full Text] [Related]
9. Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012.
Baek SK; Lee MC; Hah JH; Ahn SH; Son YI; Rho YS; Chung PS; Lee YS; Koo BS; Jung KY; Lee BJ
Head Neck; 2017 Jan; 39(1):133-139. PubMed ID: 27534388
[TBL] [Abstract][Full Text] [Related]
10. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Lee DY; Won JK; Lee SH; Park DJ; Jung KC; Sung MW; Wu HG; Kim KH; Park YJ; Hah JH
Thyroid; 2016 Mar; 26(3):404-13. PubMed ID: 26541309
[TBL] [Abstract][Full Text] [Related]
11. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
12. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany.
Wendler J; Kroiss M; Gast K; Kreissl MC; Allelein S; Lichtenauer U; Blaser R; Spitzweg C; Fassnacht M; Schott M; Führer D; Tiedje V
Eur J Endocrinol; 2016 Dec; 175(6):521-529. PubMed ID: 27926471
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and Patterns of Recurrence for Anaplastic Thyroid Cancer Treated With Comprehensive Chemoradiotherapy.
Gao RW; Foote RL; Garces YI; Ma DJ; Neben-Wittich M; Routman DM; Patel SH; Ko SJ; McGee LA; Bible KC; Chintakuntlawar AV; Ryder M; Morris JC; Van Abel KM; Rivera M; Abraha F; Lester SC
Pract Radiat Oncol; 2022; 12(2):113-119. PubMed ID: 34715395
[TBL] [Abstract][Full Text] [Related]
14. Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer.
Roche AM; Fedewa SA; Shi LL; Chen AY
Cancer; 2018 Apr; 124(8):1780-1790. PubMed ID: 29409119
[TBL] [Abstract][Full Text] [Related]
15. A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.
Chintakuntlawar AV; Yin J; Foote RL; Kasperbauer JL; Rivera M; Asmus E; Garces NI; Janus JR; Liu M; Ma DJ; Moore EJ; Morris JC; Neben-Wittich M; Price DL; Price KA; Ryder M; Van Abel KM; Hilger C; Samb E; Bible KC
Thyroid; 2019 Nov; 29(11):1615-1622. PubMed ID: 31595822
[No Abstract] [Full Text] [Related]
16. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy.
Foote RL; Molina JR; Kasperbauer JL; Lloyd RV; McIver B; Morris JC; Grant CS; Thompson GB; Richards ML; Hay ID; Smallridge RC; Bible KC
Thyroid; 2011 Jan; 21(1):25-30. PubMed ID: 21162687
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients.
Sugitani I; Miyauchi A; Sugino K; Okamoto T; Yoshida A; Suzuki S
World J Surg; 2012 Jun; 36(6):1247-54. PubMed ID: 22311136
[TBL] [Abstract][Full Text] [Related]
18. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.
Busnardo B; Daniele O; Pelizzo MR; Mazzarotto R; Nacamulli D; Devido D; Mian C; Girelli ME
J Endocrinol Invest; 2000 Dec; 23(11):755-61. PubMed ID: 11194710
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.
Jannin A; Giudici F; de la Fouchardière C; Al Ghuzlan A; Wassermann J; Chougnet CN; Drui D; Godbert Y; Ilouz F; Bardet S; Zanetta S; Roudaut N; Batisse Lignier M; Groussin L; Klein M; Zerdoud S; Lamartina L; Baudin E; Decaussin-Petrucci M; Leteurtre E; Borson Chazot F; Do Cao C; Borget I; Hadoux J;
Thyroid; 2023 Oct; 33(10):1190-1200. PubMed ID: 37855745
[No Abstract] [Full Text] [Related]
20. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
[No Abstract] [Full Text] [Related]
[Next] [New Search]
